Welcome to our dedicated page for Adocia news (Ticker: ADOCY), a resource for investors and traders seeking the latest updates and insights on Adocia stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Adocia's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Adocia's position in the market.
Adocia, a clinical-stage biopharmaceutical company, has received approval from German authorities to conduct clinical studies on its BioChaperone® Combo insulin product. These studies will aid the company's phase 3 development in China, where premix insulins constitute 65% of the market. Tonghua Dongbao will finance the program, ensuring no cash impact on Adocia. The agreement could yield up to $50 million in future payments and royalties, as BC Combo shows promise in reducing hyperglycemia and hypoglycemia compared to traditional insulins.
Adocia, a biopharmaceutical company, has successfully completed a sale and leaseback transaction of its Lyon facility for over
Adocia (Euronext Paris: ADOC) announced its fourth quarter 2021 financial results, reporting revenue of €513,000, a significant increase from €159,000 in Q4 2020. For the full year, revenue totaled €1.4 million, supported by licensing and collaboration agreements primarily with Tonghua Dongbao in Asia. However, the company’s cash position declined to €15.2 million from €28.1 million year-over-year, with net financial liabilities rising to €33.3 million. Further details on significant events and project progress will be provided on
Adocia (Euronext Paris: ADOC) has disclosed its liquidity account status as of December 31, 2021. It holds 39,816 shares valued at a cash balance of €65,112.35. In the second half of 2021, it recorded 67,820 shares bought and 61,982 shares sold, totaling €614,508.53 and €579,314.42 respectively, across 528 and 303 transactions. The liquidity contract aligns with AMF Decision n° 2021-01 from June 22, 2021. Adocia specializes in innovative therapeutic solutions for diabetes and metabolic diseases, featuring several key products in clinical and preclinical stages.
Adocia SA, a clinical-stage biopharmaceutical company in France specializing in diabetes treatments, has released its financial calendar for 2022. Key dates include revenue publications for Q4 2021 on February 23, 2022, and Q1, Q2, and Q3 revenues scheduled for May 18, August 24, and October 25, 2022, respectively. Additionally, 2021 financial statements will be published on April 19, 2022, and mid-year financials will be disclosed on September 19, 2022. Investors can access detailed information through the company's website.
FAQ
What is the market cap of Adocia (ADOCY)?
